Natural product-based therapy for pulmonary arterial hypertension: Chlorogenic acid inhibits the development of pulmonary arterial hypertension via up regulation of its target gene, 4/February/2015, 9.44 am

MiRNA based cancer therapy: MiRNA-29 inhibits cancer development by decreasing the expression of nucleotide sanitizing enzyme MTH1/NUDT1, 4/February/2014, 9.15 am
February 4, 2015
Natural product-based therapy for Human Cancer: Cirsilol suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene, 4/February/2015, 21.45
February 4, 2015
Show all

A study from the University of California, La Jolla, CA, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of Nature Medicine by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for pulmonary arterial hypertension: Chlorogenic acid inhibits the development of pulmonary arterial hypertension via up regulation of its target gene. Together, pharmacological formulations encompassing “Chlorogenic acid or its analogues may be used to treat pulmonary arterial hypertension.

Amount: $ 500*

Undisclosed information: How Chlorogenic acid  decreases pulmonary arterial hypertension

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Natural product-based therapy for pulmonary arterial hypertension: Chlorogenic acid  inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 4/February/2015,  9.45 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.